NATCO launches Bosentan Tablets for Oral Suspension in the United States with 180-day exclusivity

NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced the launch of Bosentan tablets for oral suspension (TFOS), 32mg, a generic version of Tracleer® by Actelion Pharmaceuticals US Inc. NATCO's marketing partner for the product is Lupin Limited.

NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity. They are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in paediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability.

Bosentan tablets for oral suspension (TFOS), 32mg had estimated sales of USD 10 million in the U.S. for 12 months ending June'25 as per industry sales data.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 893.25 as compared to the previous close of Rs. 874.15. The total number of shares traded during the day was 15310 in over 1012 trades.

The stock hit an intraday high of Rs. 895.45 and intraday low of 873.25. The net turnover during the day was Rs. 13544349.00.

Safe Harbor Statement

All brand names and trademarks are the property of their respective owners

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 BosentanTablets OralSuspension GenericVersion Tracleer ActelionPharmaceuticalsUSInc MarketingPartner Lupin